SEC Comment Letter 0000000000-23-003964 to Carisma Therapeutics Inc. (CARM) (CIK 0001485003) (CARM)
Carisma Therapeutics Inc. (CARM) (CIK 0001485003)
Date: April 20, 2023 · CIK: 0001485003 · Accession: 0000000000-23-003964
AI Filing Summary & Sentiment
File numbers found in text: 333-271296
Letter
United States securities and exchange commission logo April 20, 2023 Steven Kelly President and Chief Executive Officer Carisma Therapeutics Inc. 3675 Market Street, Suite 200 Philadelphia, PA 19104 Re:Carisma Therapeutics Inc. Registration Statement on Form S-3 Filed April 17, 2023 File No. 333-271296 Dear Steven Kelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Johnson
Show Raw Text
United States securities and exchange commission logo
April 20, 2023
Steven Kelly
President and Chief Executive Officer
Carisma Therapeutics Inc.
3675 Market Street, Suite 200
Philadelphia, PA 19104
Re:Carisma Therapeutics Inc.
Registration Statement on Form S-3
Filed April 17, 2023
File No. 333-271296
Dear Steven Kelly:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian Johnson